Additional work will be required to identify novel and more specific compounds able to selectively modulate TAP2 and potentially exert controlled immunomodulatory effects for patients with cancer or autoimmune diseases (e.g. compounds that could selectively reduce TAP2 expression). This evidence concerns the gene TAP2 and cancer.